{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:40Z","timestamp":1787026540314,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ40393"],"award-info":[{"award-number":["2022JJ40393"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The count of lymphocyte subsets in blood can reflect the immune status of the body which is closely related to the tumor immune microenvironment and the efficacy of NAT. This study aims to explore the relationship between peripheral blood lymphocyte subsets and the efficacy and prognosis of NAT in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed clinicopathological information and peripheral blood lymphocyte subpopulation counts of patients receiving NAT from January 2015 to November 2021 at Sun Yat-sen University Cancer Center. Kaplan-Meier curves were used to estimate the survival probability. The independent predictors of NAT response and survival prognosis were respectively analyzed by multivariate logistic regression and Cox regression, and nomograms were constructed accordingly. The prediction efficiency of three nomograms was validated separately in the training cohort and the testing cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      230 patients were included in the study, consisting of 161 in the training cohort and 69 in the testing cohort. After a median follow-up of 1238 days, patients with higher NK cell value showed higher pCR rates and higher OS and RFS after NAT (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Multivariate analyses suggested NK cell count was an independent predictor of NAT response, OS and RFS. We then built nomograms accordingly and validated the prediction performance in the testing cohort (C index for NAT response: 0.786; for OS: 0.877, for RFS: 0.794).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Peripheral blood NK cell count is a potential predictive marker for BC patients receiving NAT. Nomograms based on it might help predict NAT response and prognosis in BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1437193","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:26:32Z","timestamp":1727655992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Peripheral NK cell count predicts response and prognosis in breast cancer patients underwent neoadjuvant chemotherapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanji","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"j5913","DOI":"10.1136\/bmj.j5913","article-title":"Rethinking neoadjuvant chemotherapy for breast cancer","volume":"360","author":"Vaidya","year":"2018","journal-title":"Bmj"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdh001","article-title":"Is there still a role for neoadjuvant chemotherapy in head and neck cancer","volume":"15","author":"Licitra","year":"2004","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00022","article-title":"Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"37","author":"du Bois","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1016\/S1470-2045(17)30321-2","article-title":"Neoadjuvant chemotherapy: survival benefit in gastric cancer","volume":"18","author":"Das","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7550","article-title":"Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer","volume":"18","author":"Huang","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-11223-3","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"29","author":"Tamirisa","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2203699","DOI":"10.1002\/advs.202203699","article-title":"The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer","volume":"10","author":"Zou","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1146\/annurev-immunol-042718-041319","article-title":"New molecular insights into immune cell development","volume":"37","author":"Cumano","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2848","article-title":"Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma","volume":"23","author":"Giraldo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2011.11.002","article-title":"Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy","volume":"21","author":"Vicente Conesa","year":"2012","journal-title":"Breast"},{"key":"B23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/cam4.2019.8.issue-2","article-title":"Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer","volume":"8","author":"Yang","year":"2019","journal-title":"Cancer Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.777215","article-title":"A novel prognostic model based on the serum iron level for patients with early-stage triple-negative breast cancer","volume":"9","author":"Hua","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114514002657","article-title":"Optimal cut-off values of BMI, waist circumference and waist:height ratio for defining obesity in Chinese adults","volume":"112","author":"Zeng","year":"2014","journal-title":"Br J Nutr"},{"key":"B28","article-title":"Neoadjuvant chemotherapy in patients with stages II and III breast cancer","volume":"122","author":"Yuan","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02155-w","article-title":"Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"29","author":"Ogier du Terrail","year":"2023","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bioactmat.2023.01.014","article-title":"Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative \u201ccold\u201d triple-negative breast cancer","volume":"25","author":"Guo","year":"2023","journal-title":"Bioact Mater"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2307736","DOI":"10.1002\/smll.202307736","article-title":"Tumor microenvironment-induced drug depository for persistent antitumor chemotherapy and immune activation","volume":"20","author":"Gao","year":"2024","journal-title":"Small"},{"key":"B33","doi-asserted-by":"publisher","first-page":"110062","DOI":"10.1016\/j.biopha.2020.110062","article-title":"IMMUNEPOTENT CRP plus doxorubicin\/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model","volume":"126","author":"Santana-Kr\u00edmskaya","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9644","DOI":"10.3390\/ijms22179644","article-title":"New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer","volume":"22","author":"An","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100974","DOI":"10.1016\/j.drup.2023.100974","article-title":"GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells","volume":"69","author":"Zhu","year":"2023","journal-title":"Drug Resist Update"},{"key":"B36","doi-asserted-by":"publisher","first-page":"0247","DOI":"10.34133\/research.0247","article-title":"Remodeling tumor immune microenvironment by using polymer-lipid-manganese dioxide nanoparticles with radiation therapy to boost immune response of castration-resistant prostate cancer","volume":"6","author":"Zetrini","year":"2023","journal-title":"Res (Wash D C)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.048","article-title":"Hallmarks of tissue-resident lymphocytes","volume":"164","author":"Fan","year":"2016","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev-immunol-032712-100027","article-title":"Dynamic tuning of lymphocytes: physiological basis, mechanisms, and function","volume":"33","author":"Grossman","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8(+) T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1323","article-title":"Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer","volume":"24","author":"Afghahi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2365","article-title":"and HLA class I expression in primary HER2(+) breast cancer predict and uncouple pathological response and disease-free survival","volume":"25","author":"Muntasell","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12916-015-0540-z","article-title":"Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy","volume":"13","author":"Prat","year":"2015","journal-title":"BMC Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1470-2045(03)00961-6","article-title":"The TNM staging system and breast cancer","volume":"4","author":"Benson","year":"2003","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1437193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:26:33Z","timestamp":1727655993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1437193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2024.1437193"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1437193","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"1437193"}}